Why would an alternative to intravenous access be sought for drug administration in cases of out-of-hospital cardiac arrest? Previous trials have explored the clinical effectiveness of medications ...
Carmel Shachar is an assistant clinical professor of law and faculty director of the Health Law and Policy Clinic at Harvard Law School. Stephen Morrissey, the interviewer, is the Executive ...
Ten years ago, I was in the hospital battling Ebola. My fever rarely relented. I felt so weak that getting up was a herculean task, attempted only a few times a day. Having treated patients with ...
Zoledronate prevents fractures when given every 12 to 18 months, but its effects on bone health persist well beyond 5 years. New research findings on very infrequent zoledronate dosing in early ...
A quantitative alcohol history should be recorded for all patients, because alcohol use contributes to many physical and mental disorders. A person-centered, nonjudgmental approach should be adopted.
Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate ...
Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.
An urgent health care workforce crisis is looming. In the United States, a country plagued by disparate health outcomes across its geographic regions, relative physician “deserts” (i.e ...
Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...